Tadalafil 10 mg is a reference compound containing the active ingredient Tadalafil, a phosphodiesterase type-5 (PDE-5) inhibitor widely studied in men with erectile function and vascular response models. It is chemically identical to the compound used in the approved medication Cialis® and is frequently referenced in clinical studies for its extended half-life and sustained receptor activity.

Research Overview

In controlled trials, Tadalafil demonstrated prolonged PDE-5 enzyme inhibition, resulting in enhanced nitric oxide–mediated vasodilation within penile tissue models. Research has shown this mechanism to improve blood flow under stimulated conditions, supporting its clinical investigation in erectile function and vascular performance.

Key Research Findings

• Average onset of measurable plasma activity: 30–60 minutes post-administration
• Duration of pharmacodynamic response: up to 36 hours
• Supports evaluation of long-acting PDE-5 inhibition kinetics
• Commonly referenced as a model for “as-needed” and “daily microdose” comparison studies

Observed Outcomes in Research

• Vasodilation Response: Improved smooth-muscle relaxation and vascular perfusion in corpus cavernosum models
• Functional Outcome: Enhanced erectile response in presence of sexual stimulation (observed under clinical trial conditions)
• Duration Window: Sustained efficacy documented up to 36 hours in published trials
• Tolerability Profile: Common mild effects: headache, dyspepsia, flushing, nasal congestion (frequency <10%)

All data summarized from peer-reviewed publications on PDE-5 inhibitors and Tadalafil clinical evaluation. Presented for educational and reference purposes only.

Reference Sampling & Handling

• Form: Oral tablet (solid dose)
• Strength: 10 mg Tadalafil per tablet
• Pack Size: 10 tablets per box
• Storage: Keep below 25 °C, dry and protected from light

Reference Dosage Sampling (Based on Clinical Literature)

Reference sampling values are derived from controlled Tadalafil research protocols and are not dosing instructions for human use.

Reference Frequency & Safety Notes

• Maximum observation frequency: ≤ 1 administration per 24 hours
• Do not co-administer with nitrates or nitric-oxide donors in any model
• Observation precautions: cardiovascular function should be monitored in models simulating high vascular load
• Adverse-event profile (literature): headache, flushing, mild dyspepsia; rare optic or auditory changes

All safety data are from published clinical studies; this information is intended for research and analytical reference only.

What’s in the Box

• 10 × Tadalafil 10 mg oral tablets

Why Choose EU Pharmaceuticals?

EU Pharmaceuticals supplies verified compounds for laboratory and reference applications. Each batch undergoes independent purity and potency verification to ensure reproducibility and scientific integrity.

For laboratory, analytical, and educational use only. Not for human or veterinary ingestion or therapeutic application. No medical or performance claims are made or implied. Buyer assumes responsibility for lawful handling and compliance with local regulations.